DIABETES CARE
hamburger

PRESS RELEASES AND NOTIFICATIONS

DIABETES NEWS

ABBOTT'S FREESTYLE® LIBRE 3 SYSTEM RECEIVES CE MARK - FEATURES WORLD'S SMALLEST, THINNEST SENSOR WITH BEST-IN-CLASS PERFORMANCE AT THE SAME LOW COST FOR PEOPLE WITH DIABETES

Published on: 9.28.2020

ABBOTT PARK, Ill., Sept. 28, 2020 -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology,8 announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe. The FreeStyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones every minute, offering unsurpassed 14-day accuracy in the smallest and thinnest sensor design at the same affordable price as previous versions of the device.

ABBOTT AND TANDEM DIABETES CARE ADVANCE DEVELOPMENT OF INTEGRATED TECHNOLOGIES FOR FUTURE AUTOMATED INSULIN DELIVERY SYSTEMS

Published on: 6.29.2020

ABBOTT PARK, Ill. and SAN DIEGO, June 29, 2020 -- Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM) announced today that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading continuous glucose monitoring (CGM) technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.

NEW DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM REDUCES ALL-CAUSE, DIABETIC KETOACIDOSIS-RELATED HOSPITALIZATION RATES AND ACUTE DIABETES EVENTS

Published on: 6.16.2020

ABBOTT PARK, Ill., June 16, 2020 -- Abbott (NYSE: ABT) announced results from multiple new real-world studies that demonstrate how use of the FreeStyle Libre system, the world-leading5 continuous glucose monitoring (CGM) technology, can lead to significant clinical benefits among people living with type 1 and type 2 diabetes.

ABBOTT'S FREESTYLE® LIBRE 2 ICGM CLEARED IN U.S. FOR ADULTS AND CHILDREN WITH DIABETES, ACHIEVING HIGHEST LEVEL OF ACCURACY AND PERFORMANCE STANDARDS

Published on: 6.15.2020

ABBOTT PARK, Ill., June 15, 2020 -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes.

NEW LATE-BREAKING DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM SIGNIFICANTLY REDUCES HBA1C LEVELS IN PEOPLE WITH TYPE 2 DIABETES USING INSULIN OR NOT

Published on: 6.13.2020

ABBOTT PARK, Ill., June 13, 2020 -- Today, Abbott (NYSE: ABT) announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading continuous glucose monitoring (CGM) technology, is associated with significant reduction in hemoglobin A1c (HbA1c) levels for people living with type 2 diabetes on either long-acting insulin or non-insulin therapy.

NEW REAL-WORLD DATA SHOW THAT ABBOTT'S FREESTYLE LIBRE SYSTEM DELIVERS POSITIVE HEALTH OUTCOMES FOR PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES

Published on: 2.20.2020

- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world
- People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology

ABBOTT AND INSULET PARTNER TO INTEGRATE NEXT-GENERATION GLUCOSE SENSING AND AUTOMATED INSULIN DELIVERY TECHNOLOGIES FOR SEAMLESS DIABETES CARE

Published on: 2.19.2020

- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform
- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control

ABBOTT AND TANDEM DIABETES CARE EXPLORING NEW INTEGRATED SOLUTIONS TO IMPROVE DIABETES MANAGEMENT

Published on: 10.15.2019
ABBOTT PARK, Ill. and SAN DIEGO, Oct. 15, 2019 -- Abbott and Tandem Diabetes Care announced today that they intend to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading1 glucose sensing technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.

ABBOTT AND OMADA HEALTH PARTNER TO OFFER INTEGRATED DIGITAL HEALTH AND COACHING EXPERIENCE FOR PEOPLE WITH TYPE 2 DIABETES

Published on: 10.14.2019
ABBOTT PARK, Ill. and SAN FRANCISCO, Oct. 14, 2019 -- Abbott and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes.

ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED

Published on: 09.16.2019
ABBOTT PARK, Ill. and PARIS, Sept. 16, 2019 — Abbott and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition.

NEW DATA SHOW USE OF ABBOTT'S FREESTYLE® LIBRE SYSTEM SIGNIFICANTLY REDUCES HBA1C LEVELS IN PEOPLE LIVING WITH TYPE 2 DIABETES

Published on: 06.08.2019
Abbott (NYSE: ABT) announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring (CGM) technology, significantly reduced hemoglobin A1c (HbA1c) levels for people living with Type 2 diabetes on intensive insulin therapy.

ABBOTT'S FREESTYLE® LIBRE 2 WITH OPTIONAL REAL-TIME ALARMS SECURES CE MARK FOR USE IN EUROPE

Published on: 10.01.2018
Abbott (NYSE: ABT) today announced that it has secured CE Mark (Conformité Européenne) for its FreeStyle Libre 2 system—the next generation of FreeStyle Libre system, which safely and successfully replaces self-monitoring of blood glucose without the use of finger sticks and now offers optional glucose alarms for patients who need them.

ABBOTT'S REVOLUTIONARY CONTINUOUS GLUCOSE MONITORING SYSTEM, FREESTYLE® LIBRE, NOW AVAILABLE TO MEDICARE PATIENTS

Published on: 01.04.2018
Abbott (NYSE: ABT) today announced that the FreeStyle® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS).

NO MORE ROUTINE FINGER STICKS(1) FOR AMERICANS WITH DIABETES: ABBOTT'S FREESTYLE® LIBRE APPROVED IN THE U.S.

Published on: 09.27.2017
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre Flash Glucose Monitoring System as a replacement1 for blood glucose monitoring (BGM) for adults with diabetes in the U.S.

FREESTYLE® LIBRE FLASH GLUCOSE MONITORING TECHNOLOGY GAINS REIMBURSEMENT APPROVAL FROM THE UNITED KINGDOM'S NATIONAL HEALTH SERVICE

Published on: 09.13.2017
Abbott (NYSE: ABT) today announced that the FreeStyle® Libre system is now available for reimbursement in the United Kingdom (UK). The National Health Service (NHS) Business Services Authority has approved the listing on the Drug Tariff for the FreeStyle Libre system for people with diabetes using insulin.

REVOLUTIONARY GLUCOSE MONITORING TECHNOLOGY FREESTYLE® LIBRE NOW REIMBURSED ACROSS JAPAN

Published on: 08.31.2017
Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the FreeStyle® Libre glucose monitoring system effective September 1, 2017.

ABBOTT AND BIGFOOT BIOMEDICAL ANNOUNCE COLLABORATION TO DEVELOP BREAKTHROUGH DIABETES TECHNOLOGIES

Published on: 07.13.2017
Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technologywith Bigfoot's insulin delivery solutions in the United States.

ABBOTT SECURES HEALTH CANADA LICENSE FOR FREESTYLE® LIBRE SYSTEM FOR PEOPLE WITH DIABETES

Published on: 06.29.2017
Abbott (NYSE: ABT) today announced the Health Canada license of its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes.

ABBOTT ANNOUNCES NATIONAL REIMBURSEMENT FOR FREESTYLE® LIBRE IN FRANCE, PROVIDING ACCESS TO REVOLUTIONARY TECHNOLOGY FOR PEOPLE WITH DIABETES

Published on: 05.08.2017
Abbott today announced that the French Health Ministry has granted national reimbursement across France for FreeStyle® Libre—Abbott's revolutionary glucose monitoring technology that removes the need for routine finger sticks1 for people with diabetes.

REAL-WORLD DATA FROM ABBOTT'S FREESTYLE® LIBRE SHOW ASSOCIATION BETWEEN HIGHER FREQUENCY OF GLUCOSE MONITORING AND IMPROVED GLUCOSE CONTROL FOR PEOPLE WITH DIABETES

Published on: 02.15. 2017
Abbott (NYSE: ABT) today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels.

ABBOTT RECEIVES FDA APPROVAL FOR THE FREESTYLE LIBRE PROTM SYSTEM, A REVOLUTIONARY DIABETES SENSING TECHNOLOGY FOR HEALTHCARE PROFESSIONALS TO USE WITH THEIR PATIENTS

Published on: 09.28. 2016
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes.


ABBOTT RECEIVES APPROVAL IN AUSTRALIA FOR FREESTYLE LIBRE - THE REVOLUTIONARY GLUCOSE MONITORING SYSTEM FOR PEOPLE WITH DIABETES

Published on: 02.16.2016
Today, Abbott (NYSE:ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology.


CHILDREN IN EUROPE NOW HAVE ACCESS TO FIRST-OF-ITS-KIND DIABETES SENSING TECHNOLOGY – ELIMINATES ROUTINE FINGER PRICKS

Published on: 02.04. 2016
Today, Abbott (NYSE: ABT) announced that it has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old.

QUICK LINKS


Abbott Newsroom

ADC-01541 Ver 17.0 09/20  

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

DO YOU WISH TO LEAVE THIS SITE?

YOU ARE ABOUT TO EXIT THE ABBOTT FAMILY OF WEBSITES FOR A 3RD PARTY WEBSITE

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.

DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?

true
accessibility

NO

accessibility

YOU ARE ABOUT TO EXIT THE ABBOTT FAMILY OF WEBSITES FOR A 3RD PARTY WEBSITE

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.

DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?

accessibility

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

DO YOU WISH TO LEAVE THIS SITE?